GrittGene Therapeutics is focused on developing a cure for Myotonic Dystrophy Type 2 using CRISPR technology and artificial intelligence for precise gene editing and tissue-specific delivery. By leveraging a multidisciplinary approach and a wide range of expertise, the company aims to provide effective treatments that go beyond merely alleviating symptoms.
Funding
Funding not disclosed
Founders
Product
Problem
Myotonic Dystrophy Type 2 (DM2) is a multisystemic disorder with limited effective treatments that go beyond merely alleviating symptoms. Current approaches often fail to address the underlying genetic cause of the disease.
Solution
GrittGene Therapeutics is developing a gene-editing therapy for DM2 using CRISPR technology and artificial intelligence (AI) for precise gene editing and tissue-specific delivery. The company's approach aims to correct the genetic defect responsible for DM2, offering a potential cure rather than just managing symptoms. By combining CRISPR-based gene editing with AI-driven delivery methods, GrittGene seeks to target affected tissues with greater accuracy and efficiency. The multidisciplinary approach integrates expertise from various sectors of drug discovery to maximize the chances of success.
Target Audience
The primary target audience is individuals affected by Myotonic Dystrophy Type 2 (DM2) and the healthcare providers who treat them.
Features
- CRISPR-based gene editing for targeted correction of the DM2 genetic defect
- AI-driven tissue-specific delivery to enhance precision and minimize off-target effects
- Combination of small-molecule treatments and biologicals for a comprehensive therapeutic approach
- Global laboratories providing diagnostics solutions for clinical trials across America, Europe, and Asia